Dominik Karres
European Medicines Agency(NL)
Publications by Year
Research Areas
Childhood Cancer Survivors' Quality of Life, Pharmaceutical studies and practices, CAR-T cell therapy research, Acute Lymphoblastic Leukemia research, Neuroblastoma Research and Treatments
Most-Cited Works
- → ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients(2020)66 cited
- → Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies(2021)49 cited
- → ACCELERATE – Five years accelerating cancer drug development for children and adolescents(2022)47 cited
- → Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents(2020)43 cited
- → Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer(2021)37 cited
- → The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia(2019)36 cited
- → Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to the European Medicines Agency and US Food and Drug Administration(2020)35 cited
- → EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors(2020)28 cited
- → Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children(2020)25 cited
- → Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas(2022)23 cited